Skip to main content
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive165AccountSocial
MARKETSINVESTLIVE165
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Science and Technology

Will the FDA approve any psychedelic substance for medical use this year?

2

1
9
8
7
6
5
4
3
2
1
0
0
6
9
8
7
6
5
4
3
2
1
0
0
%

chance
▼
4
9
8
7
6
5
4
3
2
1
0
0
7
9
8
7
6
5
4
3
2
1
0
0
.
6
9
8
7
6
5
4
3
2
1
0
0

AI Digest · FDA reportedly ends fast review program as Compass Pathways files psilocybin application

Not advice · 14h ago

Kalshi traders heavily favor no FDA approval of any psychedelic drug this year, though approval gained ground over the last day. The FDA is reportedly ending a program that cut drug reviews to one or two months. Drug developer Compass Pathways filed its psilocybin application and still expects a first-half 2027 launch. Drug developer Helus Pharma said on Monday its psychedelic depression drug beat placebo in a Phase 3 trial. Serious adverse events in the study raised safety questions.

  • The Microdose

    FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin; Feds commit $25 million for ibogaine and “psychotropic” research

  • STAT

    STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions


Order book
Order book


Will the FDA approve any psychedelic substance for medical use this year?

Odds
20% chance
Max payout
Dec 31, 2026
$0
0%20%40%60%80%Jul 2025Nov 2025Mar 2026Jul 2026Nov 2026
$447,858 vol
More Science and Technology Markets

More FDA APPROVAL PSYCHEDELIC markets

Will the FDA approve any psychedelic substance for medical use before 2028?

Trending Science and Technology markets

Will the U.S. confirm that aliens exist?Best AI at the end of 2026?Where will Waymo operate this year?Google market share this weekDeepSeek market share this weekOpenRouter token usage in Nov 16–22, 2026Anthropic market share this weekOpen vs. Closed Token Volume (open weights share) today

Science and Technology hub

All Science and Technology markets